慢乙肝患者的细胞免疫与核苷类似物疗效的关系
|
摘要
一、研究慢乙肝患者Treg的表达与核苷类似物的疗效的关系。
目的:研究慢乙肝患者Treg的表达与核苷类似物的疗效的关系。
方法:用流式细胞仪检测慢乙肝患者CD4~+CD127~(lo)CD25~(hi-int)调节性T细胞占CD4~+T淋巴细胞的百分比。比较经核苷类似物治疗后不同疗效间CD4~+CD127~(lo)CD25~(hi-int)调节性T细胞的表达情况。
结果:经核苷类似物治疗后,无效组调节性T细胞(Treg)水平显著高于有效组及健康对照组,差别有统计学意义(P值分别为0.004,0.000),有效组与健康对照组之间Treg的差别无统计学意义(P＞0.05)。
结论:慢乙肝患者的Treg能够抑制机体特异的抗病毒免疫反应,所以Treg的高表达可能与HBV-DNA的高载量相关。经核苷类似物治疗后Treg的下降与低表达可能导致慢乙肝患者免疫功能的部分恢复,以利于机体内病毒的清除。因此,检测患者Treg并结合一些其它的免疫指标,将对预测核苷类似物患者远期抗病毒疗效提供一定的帮助。
二、研究慢乙肝患者IL-10,IFN-γ的表达与核苷类似物疗效的关系。
目的:研究慢乙肝患者IL-10,IFN-γ的表达与核苷类似物疗效的关系。
方法:用ELISA方法检测慢乙肝患者IL-10、IFN-γ。比较经核苷类似物治疗后不同疗效间IL-10、IFN-γ水平的差异。
结果:经核苷类似物治疗后,有效组的IFN-γ水平高于无效组及健康对照组,差别有统计学意义(P值均为0.000),无效组的IFN-γ与健康对照组相比,差别无统计学意义(P＞0.05);经核苷类似物治疗后,有效组IL-10低于无效组,差别有统计学意义(P=0.000),两组的IL-10均较健康对照组低,差别有统计学意义(P值分别为0.000,0.028)。
结论:核苷类似物治疗的疗效与IL-10与IFN-γ有一定的关系。有效组机体内反映抗病毒作用的细胞免疫指标IFN-γ的水平升高,与之相反的不利于抗病毒作用的指标IL-10的水平下降。IFN-γ是Th1细胞分泌的细胞因子,它的升高促进机体的Th1/Th2细胞之间平衡的恢复,促进机体的Th1细胞占优势,以利于机体抗病毒作用的发挥。IL-10是Th2细胞分泌的细胞因子,IL-10的降低将恢复Th1细胞的优势,降低Th2的优势,以利于机体发挥抗病毒的免疫反应。本文有关核苷类似物治疗后IL-10与IFN-γ的研究将为以后初步预测核苷类似物的疗效提供一定的帮助。
Ⅰ.Relationship between regulatory thymus cell in chronic hepatitis B patients and Nucleoside Analogues' efficacy
Objective:To study relationship between regulatory thymus cell in chronic hepatitis B patients and Nucleoside Analogues' efficacy.
Method:CD4~+CD127~(lo)CD25~(hi-int)regulatory thymus cell(Treg)was tested by Flow Cytometry.Compare Treg in patients with chronic hepatitis B virus infection under different Nucleoside Analogues' efficacy.
Result:Treg of inefficacious patients was significantly higher than eutherapeutic patients and healthy control group after Nucleoside Analogues treatment(p=0.004, p=0.000,respectively).Difference of Treg between eutherapeutic patients after Nucleoside Analogues treatment and healthy control group was showing no significant(p＞0.05).
Conclusion:Treg of chronic hepatitis B can inhibit antiviral immune response,so the high expression of Treg was correlated with the high viral load in chronic hepatitis B virus infection.The low expression and decrease of Treg could result in partial recovery of immune function in chronic hepatitis B after Nucleoside Analogue treatment,so it would be beneficial to viral clearance.Detection Treg and other immune index would provide help for preliminary prediction efficacy of Nucleoside Analogue treatment.
Ⅱ:Relationship between Interferon-γ(IFN-γ)and Interleukin-10(IL-10)in chronic hepatitis B patients and Nucleoside Analogues' efficacy
Objective:To study relationship between IFN-γand IL-10 in chronic hepatitis B patients with and Nucleoside Analogues' efficacy.
Method:IFN-γand IL-10 in chronic hepatitis B patients after Nucleoside Analogue treatment testing by Enzyme-linked Immunosorbent Assay(ELISA).Compare the IFN-γand IL-10 in chronic hepatitis B patients under different Nucleoside Analogues efficacy.
Result:IFN-γof eutherapeutic patients was significantly higher than inefficacious patients and healthy control group(p=0.000,p=0.000,respectively).Differences of IFN-γbetween inefficacious patients and healthy control group was no significant( p＞0.05).IL-10 of eutherapeutic patients was significantly lower than inefficacious patients(p=0.000).IL-10 of eutherapeutic patients and inefficacious patients after Nucleoside Analogue treatment was significantly lower than healthy control group (p=0.000,p=0.028,respectively).
Conclusion:IFN-γand IL-10 was correlated with efficacy of Nucleoside Analogues treatment.IFN-γwhich inflects antiviral immune response was increased.IL-10 which go against antiviral immune response was decreased.IFN-γwas secreted by thymus helper 1(Th1)cell.The increased of IFN-γpromote the balance of Th1/Th2, which was beneficial to viral clearance.IL-10 was secreted by Th2 cell.The decreased of IL-10 recovered the superiority of Th1,which was beneficial to viral clearance.This study about IFN-γand IL-10 would provide help for preliminary prediction of Nucleoside Analogues' efficacy.
目的:研究慢乙肝患者Treg的表达与核苷类似物的疗效的关系。
方法:用流式细胞仪检测慢乙肝患者CD4~+CD127~(lo)CD25~(hi-int)调节性T细胞占CD4~+T淋巴细胞的百分比。比较经核苷类似物治疗后不同疗效间CD4~+CD127~(lo)CD25~(hi-int)调节性T细胞的表达情况。
结果:经核苷类似物治疗后,无效组调节性T细胞(Treg)水平显著高于有效组及健康对照组,差别有统计学意义(P值分别为0.004,0.000),有效组与健康对照组之间Treg的差别无统计学意义(P＞0.05)。
结论:慢乙肝患者的Treg能够抑制机体特异的抗病毒免疫反应,所以Treg的高表达可能与HBV-DNA的高载量相关。经核苷类似物治疗后Treg的下降与低表达可能导致慢乙肝患者免疫功能的部分恢复,以利于机体内病毒的清除。因此,检测患者Treg并结合一些其它的免疫指标,将对预测核苷类似物患者远期抗病毒疗效提供一定的帮助。
二、研究慢乙肝患者IL-10,IFN-γ的表达与核苷类似物疗效的关系。
目的:研究慢乙肝患者IL-10,IFN-γ的表达与核苷类似物疗效的关系。
方法:用ELISA方法检测慢乙肝患者IL-10、IFN-γ。比较经核苷类似物治疗后不同疗效间IL-10、IFN-γ水平的差异。
结果:经核苷类似物治疗后,有效组的IFN-γ水平高于无效组及健康对照组,差别有统计学意义(P值均为0.000),无效组的IFN-γ与健康对照组相比,差别无统计学意义(P＞0.05);经核苷类似物治疗后,有效组IL-10低于无效组,差别有统计学意义(P=0.000),两组的IL-10均较健康对照组低,差别有统计学意义(P值分别为0.000,0.028)。
结论:核苷类似物治疗的疗效与IL-10与IFN-γ有一定的关系。有效组机体内反映抗病毒作用的细胞免疫指标IFN-γ的水平升高,与之相反的不利于抗病毒作用的指标IL-10的水平下降。IFN-γ是Th1细胞分泌的细胞因子,它的升高促进机体的Th1/Th2细胞之间平衡的恢复,促进机体的Th1细胞占优势,以利于机体抗病毒作用的发挥。IL-10是Th2细胞分泌的细胞因子,IL-10的降低将恢复Th1细胞的优势,降低Th2的优势,以利于机体发挥抗病毒的免疫反应。本文有关核苷类似物治疗后IL-10与IFN-γ的研究将为以后初步预测核苷类似物的疗效提供一定的帮助。
Ⅰ.Relationship between regulatory thymus cell in chronic hepatitis B patients and Nucleoside Analogues' efficacy
Objective:To study relationship between regulatory thymus cell in chronic hepatitis B patients and Nucleoside Analogues' efficacy.
Method:CD4~+CD127~(lo)CD25~(hi-int)regulatory thymus cell(Treg)was tested by Flow Cytometry.Compare Treg in patients with chronic hepatitis B virus infection under different Nucleoside Analogues' efficacy.
Result:Treg of inefficacious patients was significantly higher than eutherapeutic patients and healthy control group after Nucleoside Analogues treatment(p=0.004, p=0.000,respectively).Difference of Treg between eutherapeutic patients after Nucleoside Analogues treatment and healthy control group was showing no significant(p＞0.05).
Conclusion:Treg of chronic hepatitis B can inhibit antiviral immune response,so the high expression of Treg was correlated with the high viral load in chronic hepatitis B virus infection.The low expression and decrease of Treg could result in partial recovery of immune function in chronic hepatitis B after Nucleoside Analogue treatment,so it would be beneficial to viral clearance.Detection Treg and other immune index would provide help for preliminary prediction efficacy of Nucleoside Analogue treatment.
Ⅱ:Relationship between Interferon-γ(IFN-γ)and Interleukin-10(IL-10)in chronic hepatitis B patients and Nucleoside Analogues' efficacy
Objective:To study relationship between IFN-γand IL-10 in chronic hepatitis B patients with and Nucleoside Analogues' efficacy.
Method:IFN-γand IL-10 in chronic hepatitis B patients after Nucleoside Analogue treatment testing by Enzyme-linked Immunosorbent Assay(ELISA).Compare the IFN-γand IL-10 in chronic hepatitis B patients under different Nucleoside Analogues efficacy.
Result:IFN-γof eutherapeutic patients was significantly higher than inefficacious patients and healthy control group(p=0.000,p=0.000,respectively).Differences of IFN-γbetween inefficacious patients and healthy control group was no significant( p＞0.05).IL-10 of eutherapeutic patients was significantly lower than inefficacious patients(p=0.000).IL-10 of eutherapeutic patients and inefficacious patients after Nucleoside Analogue treatment was significantly lower than healthy control group (p=0.000,p=0.028,respectively).
Conclusion:IFN-γand IL-10 was correlated with efficacy of Nucleoside Analogues treatment.IFN-γwhich inflects antiviral immune response was increased.IL-10 which go against antiviral immune response was decreased.IFN-γwas secreted by thymus helper 1(Th1)cell.The increased of IFN-γpromote the balance of Th1/Th2, which was beneficial to viral clearance.IL-10 was secreted by Th2 cell.The decreased of IL-10 recovered the superiority of Th1,which was beneficial to viral clearance.This study about IFN-γand IL-10 would provide help for preliminary prediction of Nucleoside Analogues' efficacy.
引文
[1]Chen RY,Edward R,Shaw I,et al.Effect of the G1896A precore mutation on drug sensitivity and replication yield of lamivudine-resistant HBV in vitro[J ].Hepatology,2003,37:27-35.
[2]严伟明.免疫系统在病毒性肝炎发病中的作用[J].中华肝脏病杂志,2008.16(2):81-83。
[3]于贤杰,王贵强.慢性乙型肝炎的免疫治疗[J].世界华人消化杂志,2007.15(16):1835-1840.
[4]Roncarolo MG,Levings MK.The role of different subsets of T regulatory cells in controlling autoimmunity[J].Curr Opin Immunol,2000,12:676-683.
[5]Hori S,Nomura T,Sakaguchi S.Control of regulatory T cell development by the transcription factor Foxp3[J].Science,2003,299:1057-1061.
[6]王敏,张玲霞,罗生强.慢性乙型肝炎患者抗病毒治疗前后HBV特异性T细胞反应[J].中华实验和临床病毒学杂志,2005,19(4):387-390.
[7]Amir S and Yosef S.Inhibition of Hepatitis B Virus Expression and Replication By RNA Interference[J].Hepatology,2003,37:764-770.
[8]Lee M,Lee S K,Son M,et al.Expression of Thl and Th2 type cytokines responding to HBsAg and HBxAg in chronic hepatitis B patient[J].J Koren Men Sci,1999,14:175-181.
[9]张萍,颜学真,吴文漪等.慢性乙型肝炎患者外周血单个核细胞Th1,Th2型细胞标志物及其细胞因子的表达[J].中华传染病杂志,2003,21(1):42-43.
[10]周茂华,王丁,张建军等.乙型肝炎患者外周血细胞中Th1/Th2型细胞因子的表达及其临床意义[J].中国免疫学杂志,2003,8(10):725-727
[11]He XS,Rehermann B,Boisvert J,et al.Direct functional analysis of epi 2tope specific CD8~+ T cells in peripheral blood[J].Viral Immunol,2001,14(1):59-69.
[12]Stoop J N,Van der Molen RG,Baan CC,et al.Regulatory T cells con2tribute to the impaired immune response in patients with chronic hepatitis B virus infection[J].Hepatology,2005,41(4):771-778.
[13]Franzese O,Kennedy PT,Gehring AJ,et al.Modulation of the CD8~+ T-cell response by CD4~+ CD25~+ regulatory T cells in patients with hepatitis B virus infection[J].J Virol,2005,79(6):3322-3328.
[14]Bluestone JA,Abbas AK.Natural versus adaptive regulatory T cells[J].Nat Rev Immunol,2003,3:253-257.
[15]Paust S,Cantor H.Regulatory T cells and autoimmune disease[J].Irnmunol Rev,2005,204:195-207.
[16]周立平,陈昕,巴静等.HBV感染后外周血CD4~+CD25~+Foxp3~+调节性T细胞与疾病进展的相关性[J].世界华人消化杂志,2007,15(21):2366-2369.
[17]Fontenot JD,Rudensky AY.A well adapted regulatory contrivance:regulatory T cell development and the forkhead family transcription factor Foxp3[J].Nat Immunol,2005,6(4):331-337.
[18]Xu D,Fu J,Jin L,et al.Circulation and liver resident CD4+CD25+regulatory T cells actively influence the antiviral immune response and disease progression in patients with hepatitis B[J].J Immunol,2006,177(1):739-747.
[19]Morgan ME,van Bilsen JH,Bakker AM,et al.Expression of FoxP3 mRNA is not confined to CD4~+CD25~+ T regulatory cells in humans[J].Hum Immunol,2005,66:13-20.
[20]Verhasselt V,Vosters O,Beuneu C,et al.Induction of FOXP3-expressing regulatory CD4pos T cells by human mature autologous dendritic cells[J].Eur J Immunol,2004,34:762-772.
[21]Maloy KJ,Salaun L,Cahill R,Dougan G,et al.Powrie F.CD4~+CD25~+ T(R)cells suppress innate immune pathology through cytokine-dependent mechanisms[J].J Exp Med,2003,197:111-119.
[22]Zheng SG,Wang JH,Gray JD,Soucier H,Horwitz DA.Natural and induced CD4~+CD25~+cells educate CD4~+CD25~+cells to develop suppressive activity:the role ofIL-2,TGF-beta,and IL-10[J].J Immunol,2004,172:5213-5221.
[23]Kingsley CI,Karim M,Bushell AR,Wood KJ.CD25~+CD4~+regulatory T cells prevent graft rejection:CTLA-4-and IL-10-dependent immunoregulation of alloresponses[J].J Immunol,2002,168:1080-1086.
[24]Earle KE,Tang Q,Zhou X,et al.In vitro expanded human CD4~+CD25~+ regulatory T cells suppress effectors T cell proliferation[J].Clin Immunol,2005,115(1):3-9.
[25]Kondo Y,Kobayashi K,Ueno Y.Mechanism of T cell hyporesponsiveness to HBcAg is associated with regulatory T cells in chronic hepatitis B[J].World J Gastroenterol,2006,21:12(27):4310-7.
[26]沈俊辉,李宁,范学工.慢性乙型肝炎患者CD4~+CD25~+调节性T细胞的检测及意义[J].世界华人消化杂志,2007,15(26):2790-2795.
[27]Xu D,Fu J,Jin L,Wang FS,et al.Circulating and Liver Resident CD4~+CD25~+ Regulatory T Cells Actively Influence the Antiviral Immune Response and Disease Progression in Patients with Hepatitis B[J].J Immunol,2006,1,177(1):739-47.
[28]Liu W,Putnam AL,Xu-Yu Z,et al.CD127 expression inversely correlates with Foxp3 and supressive function of human CD4~+ Treg cells[J].J Exp Med 2006,203:1701-1711.
[29]Seddiki N,Santner-Nanan B,Martinson J,et al.Expression of interleukin (IL)-2 and IL-7 receptors discriminates between human regulatory and activated T cells[J].J Exp Med 2006,203:1693-1700.
[30]张恒芳,郭芳,费然等.CD4~+CD25~+调节性T细胞在慢性乙肝患者的免疫机制中的作用[J].世界华人消化杂志,2007,15(20):2225-2230.
[31]R Mohamed,P Desmond,D Jin Suh,et al.Practical difficulties in the management of hepatitis B in the Asia-Pacific region[J].J Gastroenterol Hepatol,2004,19:958-969.
[32]Lok AS,McMahon BJ.Chronic hepatitis B[J].Hepatology,2001,34:1225-41.
[33]Rapicetta M,Ferrari C,Levrero M.Viral determinants and host immune responses in the pathogenesis of HBV infection[J].J Med Virol,2002,67:454-457.
[34]Thimme R,Pemberrton J,Chisari FV,et al.Analysis of a successful immune response against HBV[J].Hepatology,2000,32:392-399.
[35]Webster G,Reihnat S,Maini MK,et al.Incubation phase of acute hepatitis B in man:dynamic of cellular immune mechanisms[J].Hepatology,2000,32(5):1117-1124.
[36] He X S, Rehermann B, Lopez Labrador F X, et al. Quantitative analysis of hepatitis C virus2specific CD8~+ T cells in peripheral blood and liver using peptide-MHC tetramers [J]. Proc Natl Acad Sci USA, 1999 , 96 (10): 5692 - 5697.
[37] By Mala K, Maini, Carolina Boni, Chun Kyon Lee. The role of virus-specific CD8 cells in liver damage and viral control during persistent Hepatitis B virus iInfection [J]. J Exp Med, Volume 191, (8): 1269-1280.
[38] Chee-Kin Hui, George K.K. Lau. Immune system and hepatitis B virus infection [J]. Journal of Clinical Virology, 2005,34 (1) : S44-S48.
[39] Sitia G, Isogawa M, Iannacone M, et al. MMPs are required for recruit2 ment of antigen - nonspecific mononuclear cells into the liver by CTL [J] . J Clin Invest, 2004 ,113(8): 1158-1167.
[40] Guidotti LG , Chisari FV . Immunobiology and pathogenesis of viral hepatitis [J] . Annu Rev Pathol Mech Dis, 2006, 1 :23 - 61.
[41] Appay V, Dunbar PR, CallanM, et al. Memory CD8~+ T cells vary differentiation phenotype in different persistent virus infections [J]. Nat Med, 2002 , 8(4): 379 - 385.
[42] Suvas S , Kumaraguru U , Pack CD , et al . CD4~+ CD25~+ T cells regulate virus - specific primary and memory CD8~+ T cell responses [J]. J Exp Med, 2003 ,198(6) :889-901.
[43] Thimme R , Wieland S , Steiger C , et al . CD8~+ T cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection [J]. J Virol, 2003 ,77(1): 68 - 76.
[44] Janssen EM, Lemmens EE , Wolfe T,et al . CD4 T cells are required for secondary expansion and memory in CD8 T lymphocytes [J] .Nature, 2003 , 421 (6925) :852 - 856.
[45] Sun JC, Bevan MJ. Defective CD8 T cell memory following acute infection without CD4 T cell help [J] . Science , 2003 ,300(5617): 339 - 342.
[46] Shedlock DJ , Shen H. Requirement for CD4 T cell help in generating func2 tional CD8 T cell memory [J] .Science, 2003 , 300(5617) :337 - 339.
[47] Bertoletti A, Gehring AJ. The immune response during hepatitis B virus infection [J]. J Gen Virol, 2006, 87(6): 1439-49.
[48]XING Tongjing,ZHANG Lian,LU Qiaosheng.Th1/Th2 type cytokines in hepatitis B patients treated with interferon-α[J].Chinese Medical Journal,2001,114(9):921-924
[49]Jiang RL,Feng XR,Guo YB,et al.T helper cells in patients with chronic hepatitis B virus infection[J].Chinese Medical Journal,2002,115(3):422-424.
[50]Falasca K,Ucciferri C,Dalessandro M,et al.Cytokine patterns correlate with liver damage in patients with chronic hepatitis B and C[J].Ann Clin Lab Sci.2006,36(2):144-50.
[51]Dai W,Yu W,Jiang R,et al.IFN-γ/IL-4 expression in peripheral blood mononuclear cells of the patients with chronic severe hepatitis[J].Zhong hua Gan Zang Bing Za Zhi,2001,9,64-65.
[52]Ferrara J.Cytokines and the regulation of tolerance[J].J Clin Invest,2000,105(8):1043-1044.
[53]Roncarlo MG,Levins M.The role of different subsets of T regulation cell in controlling autoimmunity[J].Curr Opin Immunol,2000,12(6):676-683.
[54]Agrawal S,Agrawal A,Doughty B,et al.Cutting edge:different Toll-like receptor agonists instruct dendritic cells to induce distinct Th responses via differential modulation of extracellular signal-regulated kinase-mitogen-activated protein kinase and c-Fos[J].J Immunol,2003,171(1):4984-4989.
[55]游晶,庄林,马永良.慢性乙型肝炎的Th细胞亚群及相关细胞因子网络失衡[J].世界华人消化杂志,2007,15(8):791-799.
[56]孙巧玲,李定国.IL-10与肝脏疾病[J].国际消化病杂志,2007,27(4):258-260.
[57]Fukuda R,Ishimura N,Nguyen TX,et al.The expression of IL-2,IL-4and interferon-gamma(IFN-gamma)mRNA using liver biopsies at different phases of acute exacerbation of chronic hepatitis B[J].Chin EXP Immunol,1995,100(3):446-451.
[58]Dong Y,Xi H,Yu Y,et al.Effects of oxymatrine on the serum levels of T helper cell 1 and 2 cytokines and the expression of the S gene in hepatitis B virus S gene transgenic mice:a study on the anti-hepatitis B virus mechanism of oxymatrine [J] . J Gastroenterol Hepatol, 2002 ,17(2): 1299 -1306.
[59] Matima G, Roasol S, Cameei P, et al. Immunopathogenesis of hepatitis B virus recurrence after liver transplantation [J] .Transplantation, 2000, 69(12): 559 -568.
[1]R Mohamed,P Desmond,D Jin Suh,et al.Practical difficulties in the management of hepatitis B in the Asia-Pacific region[J].J Gastroenterol Hepatol,2004,19:958-969.
[2]Huang CF,Lin SS,Ho YC.The immune response induced by hepatitis B virus principal antigens[J].Cell Mol Immunol,2006,3(2):97-106.
[3]徐承富,厉有名.NKT细胞与肝脏疾病[J],中华肝脏病杂志,2007,15(5):399-400.
[4]邢汉前,辛绍杰,陈黎明.慢性乙型肝炎病毒感染的免疫机制[J].国际流行病学传染病杂志,2006,33(3)177-180.
[5]Huang Y,Chen Z,Jia H,et al.Induction of Tcl response and enhanced cytotoxic T lymphocyte activity in mice by dendritic cells transduced with adenovirus expressing HBsAg[J].Clin Immunol 2006;119:280-290.
[6]Fu-Sheng Wang,Li-He Xing,Ming-Xu Liu,et al.Dysfunction of peripheral blood dendritic cells from patients with chronic hepatitis B virus infection[J].World J Gastroenterol,2001,7(4):537-541.
[7]刘庆峰,张政,姚金霞等.CpG ODN2216刺激慢性乙型肝炎患者浆样树突状细胞表型和功能的变化[J].中华肝脏病杂志,2006,14(10):725-728.
[8]王凯,陈龙岩,王兵等.慢性乙型肝炎患者树突状细胞表型的研究[J].中华实验和临床病毒学杂志,2006,20(3):250-253.
[9]Zhang Z,Chen D,Yao J.Increased infiltration of intrahepatic DC subsetients with chronic hepatitis B[J].Clin Immunol,2007,122(2):173-180.
[10]陈明泉,施光峰,卢清等.不同病毒载量的慢性乙型肝炎患者外周血树突状细胞的表型和功能[J].中华肝脏病杂志,2007,15(1):19-23.
[11]Amir S and Yosef S.Inhibition of hepatitis B virus expression and replication by RNA interference[J].Hepatology,2003,37:764-770.
[12]何登明,毛青,王宇明等.慢性乙型肝炎患者拉米夫定治疗前后血清IL-2和IFN-γ水平变化[J].实用肝脏病杂志,2004,7(2):91-93.
[13]Falasca K,Ucciferri C,Dalessandro M,etal.Cytokine patterns correlate with liver damage in patients with chronic hepatitis B and[J]C.Ann Clin Lab Sci.2006Spring;36(2):144-150.
[14]Rigopoulou EI,Suri D,Chokshi S,et al.Lamivudine plus interleukin-12combination therapy in chronic hepatitis B:antiviral and immunological activity[J].Hepatology,2005,42(5):1028-1036.
[15]马清峰,王威,李丽等.慢性乙型肝炎患者血清和外周血单个核细胞IL-18水平与HBV感染的关系[J].肝脏,2007,12(2):112-114.
[16]Roncarolo MG,Levings MK.The role of different subsets of T regulatory cells in controlling autoimmunity[J].Curr Opin Immunol,2000,12:676-683.
[17]Hori S,Nomura T,Sakaguchi S.Control of regulatory T cell development by the transcripti-on factor Foxp3[J].Science,2003,299:1057-1061.
[18]Shevach EM,McHugh RS,Piccirillo CA,Thomton AM.Control of T-cell activation by CD4~+CD25~+ suppressor T cells[J].Immunol Rev,2001,182:58-67.
[19]Kondo Y,Kobayashi K,Ueno Y.Mechanism of Y cell hyporesponsiveness to HBcAg is associated with regulatory T cells in chronic hepatitis B[J].World J Gastroenterol,2006,21:12(27):4310-4317.
[20]Franzese O,Kennedy PT,Gehring AJ,et al.Modulation of the CD8+T cell response by CD4+CD25+ regulatory T cells in patients with hepatitis B virus infection[J].J Virol,2005,79:3322-3328.
[21]Xu D,Fu J,Jin L,Wang FS,et al.Circulating and Liver Resident CD4~+CD25~+Regulatory T Cells Actively Influence the Antiviral Immune Response and Disease Progression in Patients with Hepatitis B[J].J Immunol,2006,1;177(1):739-747.
[22]福军亮,徐东平,赵平等.急慢性乙型肝炎患者外周血调节性T细胞鉴定与临床意义分析[J].中华医学杂志,2006,86(22):1522-1525.
[23]Stoop JN,van der Molen RG,Kuipers EJ.Inhibition of viral replication reduces regulatory T cells and enhances the antiviral immune response in chronic hepatitis B[J].Virology,2007,361,1(25):141-148.
[24]福军亮,徐东平,施明等.乙型肝炎患者外周血CD4~+CD25~+调节性T细胞表型与功能分析[J].中华内科杂志,2006,45(8):642-645.
[25]Bauer T,Gunther M,Bienzle U.Vaccination against hepatitis B in liver transplant recipients:Pilot analysis of cellular immune response shows evidence of HBsAg-specific regulatory T cells[J].Liver Transpl,2007,13(3):434-442.
[2]严伟明.免疫系统在病毒性肝炎发病中的作用[J].中华肝脏病杂志,2008.16(2):81-83。
[3]于贤杰,王贵强.慢性乙型肝炎的免疫治疗[J].世界华人消化杂志,2007.15(16):1835-1840.
[4]Roncarolo MG,Levings MK.The role of different subsets of T regulatory cells in controlling autoimmunity[J].Curr Opin Immunol,2000,12:676-683.
[5]Hori S,Nomura T,Sakaguchi S.Control of regulatory T cell development by the transcription factor Foxp3[J].Science,2003,299:1057-1061.
[6]王敏,张玲霞,罗生强.慢性乙型肝炎患者抗病毒治疗前后HBV特异性T细胞反应[J].中华实验和临床病毒学杂志,2005,19(4):387-390.
[7]Amir S and Yosef S.Inhibition of Hepatitis B Virus Expression and Replication By RNA Interference[J].Hepatology,2003,37:764-770.
[8]Lee M,Lee S K,Son M,et al.Expression of Thl and Th2 type cytokines responding to HBsAg and HBxAg in chronic hepatitis B patient[J].J Koren Men Sci,1999,14:175-181.
[9]张萍,颜学真,吴文漪等.慢性乙型肝炎患者外周血单个核细胞Th1,Th2型细胞标志物及其细胞因子的表达[J].中华传染病杂志,2003,21(1):42-43.
[10]周茂华,王丁,张建军等.乙型肝炎患者外周血细胞中Th1/Th2型细胞因子的表达及其临床意义[J].中国免疫学杂志,2003,8(10):725-727
[11]He XS,Rehermann B,Boisvert J,et al.Direct functional analysis of epi 2tope specific CD8~+ T cells in peripheral blood[J].Viral Immunol,2001,14(1):59-69.
[12]Stoop J N,Van der Molen RG,Baan CC,et al.Regulatory T cells con2tribute to the impaired immune response in patients with chronic hepatitis B virus infection[J].Hepatology,2005,41(4):771-778.
[13]Franzese O,Kennedy PT,Gehring AJ,et al.Modulation of the CD8~+ T-cell response by CD4~+ CD25~+ regulatory T cells in patients with hepatitis B virus infection[J].J Virol,2005,79(6):3322-3328.
[14]Bluestone JA,Abbas AK.Natural versus adaptive regulatory T cells[J].Nat Rev Immunol,2003,3:253-257.
[15]Paust S,Cantor H.Regulatory T cells and autoimmune disease[J].Irnmunol Rev,2005,204:195-207.
[16]周立平,陈昕,巴静等.HBV感染后外周血CD4~+CD25~+Foxp3~+调节性T细胞与疾病进展的相关性[J].世界华人消化杂志,2007,15(21):2366-2369.
[17]Fontenot JD,Rudensky AY.A well adapted regulatory contrivance:regulatory T cell development and the forkhead family transcription factor Foxp3[J].Nat Immunol,2005,6(4):331-337.
[18]Xu D,Fu J,Jin L,et al.Circulation and liver resident CD4+CD25+regulatory T cells actively influence the antiviral immune response and disease progression in patients with hepatitis B[J].J Immunol,2006,177(1):739-747.
[19]Morgan ME,van Bilsen JH,Bakker AM,et al.Expression of FoxP3 mRNA is not confined to CD4~+CD25~+ T regulatory cells in humans[J].Hum Immunol,2005,66:13-20.
[20]Verhasselt V,Vosters O,Beuneu C,et al.Induction of FOXP3-expressing regulatory CD4pos T cells by human mature autologous dendritic cells[J].Eur J Immunol,2004,34:762-772.
[21]Maloy KJ,Salaun L,Cahill R,Dougan G,et al.Powrie F.CD4~+CD25~+ T(R)cells suppress innate immune pathology through cytokine-dependent mechanisms[J].J Exp Med,2003,197:111-119.
[22]Zheng SG,Wang JH,Gray JD,Soucier H,Horwitz DA.Natural and induced CD4~+CD25~+cells educate CD4~+CD25~+cells to develop suppressive activity:the role ofIL-2,TGF-beta,and IL-10[J].J Immunol,2004,172:5213-5221.
[23]Kingsley CI,Karim M,Bushell AR,Wood KJ.CD25~+CD4~+regulatory T cells prevent graft rejection:CTLA-4-and IL-10-dependent immunoregulation of alloresponses[J].J Immunol,2002,168:1080-1086.
[24]Earle KE,Tang Q,Zhou X,et al.In vitro expanded human CD4~+CD25~+ regulatory T cells suppress effectors T cell proliferation[J].Clin Immunol,2005,115(1):3-9.
[25]Kondo Y,Kobayashi K,Ueno Y.Mechanism of T cell hyporesponsiveness to HBcAg is associated with regulatory T cells in chronic hepatitis B[J].World J Gastroenterol,2006,21:12(27):4310-7.
[26]沈俊辉,李宁,范学工.慢性乙型肝炎患者CD4~+CD25~+调节性T细胞的检测及意义[J].世界华人消化杂志,2007,15(26):2790-2795.
[27]Xu D,Fu J,Jin L,Wang FS,et al.Circulating and Liver Resident CD4~+CD25~+ Regulatory T Cells Actively Influence the Antiviral Immune Response and Disease Progression in Patients with Hepatitis B[J].J Immunol,2006,1,177(1):739-47.
[28]Liu W,Putnam AL,Xu-Yu Z,et al.CD127 expression inversely correlates with Foxp3 and supressive function of human CD4~+ Treg cells[J].J Exp Med 2006,203:1701-1711.
[29]Seddiki N,Santner-Nanan B,Martinson J,et al.Expression of interleukin (IL)-2 and IL-7 receptors discriminates between human regulatory and activated T cells[J].J Exp Med 2006,203:1693-1700.
[30]张恒芳,郭芳,费然等.CD4~+CD25~+调节性T细胞在慢性乙肝患者的免疫机制中的作用[J].世界华人消化杂志,2007,15(20):2225-2230.
[31]R Mohamed,P Desmond,D Jin Suh,et al.Practical difficulties in the management of hepatitis B in the Asia-Pacific region[J].J Gastroenterol Hepatol,2004,19:958-969.
[32]Lok AS,McMahon BJ.Chronic hepatitis B[J].Hepatology,2001,34:1225-41.
[33]Rapicetta M,Ferrari C,Levrero M.Viral determinants and host immune responses in the pathogenesis of HBV infection[J].J Med Virol,2002,67:454-457.
[34]Thimme R,Pemberrton J,Chisari FV,et al.Analysis of a successful immune response against HBV[J].Hepatology,2000,32:392-399.
[35]Webster G,Reihnat S,Maini MK,et al.Incubation phase of acute hepatitis B in man:dynamic of cellular immune mechanisms[J].Hepatology,2000,32(5):1117-1124.
[36] He X S, Rehermann B, Lopez Labrador F X, et al. Quantitative analysis of hepatitis C virus2specific CD8~+ T cells in peripheral blood and liver using peptide-MHC tetramers [J]. Proc Natl Acad Sci USA, 1999 , 96 (10): 5692 - 5697.
[37] By Mala K, Maini, Carolina Boni, Chun Kyon Lee. The role of virus-specific CD8 cells in liver damage and viral control during persistent Hepatitis B virus iInfection [J]. J Exp Med, Volume 191, (8): 1269-1280.
[38] Chee-Kin Hui, George K.K. Lau. Immune system and hepatitis B virus infection [J]. Journal of Clinical Virology, 2005,34 (1) : S44-S48.
[39] Sitia G, Isogawa M, Iannacone M, et al. MMPs are required for recruit2 ment of antigen - nonspecific mononuclear cells into the liver by CTL [J] . J Clin Invest, 2004 ,113(8): 1158-1167.
[40] Guidotti LG , Chisari FV . Immunobiology and pathogenesis of viral hepatitis [J] . Annu Rev Pathol Mech Dis, 2006, 1 :23 - 61.
[41] Appay V, Dunbar PR, CallanM, et al. Memory CD8~+ T cells vary differentiation phenotype in different persistent virus infections [J]. Nat Med, 2002 , 8(4): 379 - 385.
[42] Suvas S , Kumaraguru U , Pack CD , et al . CD4~+ CD25~+ T cells regulate virus - specific primary and memory CD8~+ T cell responses [J]. J Exp Med, 2003 ,198(6) :889-901.
[43] Thimme R , Wieland S , Steiger C , et al . CD8~+ T cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection [J]. J Virol, 2003 ,77(1): 68 - 76.
[44] Janssen EM, Lemmens EE , Wolfe T,et al . CD4 T cells are required for secondary expansion and memory in CD8 T lymphocytes [J] .Nature, 2003 , 421 (6925) :852 - 856.
[45] Sun JC, Bevan MJ. Defective CD8 T cell memory following acute infection without CD4 T cell help [J] . Science , 2003 ,300(5617): 339 - 342.
[46] Shedlock DJ , Shen H. Requirement for CD4 T cell help in generating func2 tional CD8 T cell memory [J] .Science, 2003 , 300(5617) :337 - 339.
[47] Bertoletti A, Gehring AJ. The immune response during hepatitis B virus infection [J]. J Gen Virol, 2006, 87(6): 1439-49.
[48]XING Tongjing,ZHANG Lian,LU Qiaosheng.Th1/Th2 type cytokines in hepatitis B patients treated with interferon-α[J].Chinese Medical Journal,2001,114(9):921-924
[49]Jiang RL,Feng XR,Guo YB,et al.T helper cells in patients with chronic hepatitis B virus infection[J].Chinese Medical Journal,2002,115(3):422-424.
[50]Falasca K,Ucciferri C,Dalessandro M,et al.Cytokine patterns correlate with liver damage in patients with chronic hepatitis B and C[J].Ann Clin Lab Sci.2006,36(2):144-50.
[51]Dai W,Yu W,Jiang R,et al.IFN-γ/IL-4 expression in peripheral blood mononuclear cells of the patients with chronic severe hepatitis[J].Zhong hua Gan Zang Bing Za Zhi,2001,9,64-65.
[52]Ferrara J.Cytokines and the regulation of tolerance[J].J Clin Invest,2000,105(8):1043-1044.
[53]Roncarlo MG,Levins M.The role of different subsets of T regulation cell in controlling autoimmunity[J].Curr Opin Immunol,2000,12(6):676-683.
[54]Agrawal S,Agrawal A,Doughty B,et al.Cutting edge:different Toll-like receptor agonists instruct dendritic cells to induce distinct Th responses via differential modulation of extracellular signal-regulated kinase-mitogen-activated protein kinase and c-Fos[J].J Immunol,2003,171(1):4984-4989.
[55]游晶,庄林,马永良.慢性乙型肝炎的Th细胞亚群及相关细胞因子网络失衡[J].世界华人消化杂志,2007,15(8):791-799.
[56]孙巧玲,李定国.IL-10与肝脏疾病[J].国际消化病杂志,2007,27(4):258-260.
[57]Fukuda R,Ishimura N,Nguyen TX,et al.The expression of IL-2,IL-4and interferon-gamma(IFN-gamma)mRNA using liver biopsies at different phases of acute exacerbation of chronic hepatitis B[J].Chin EXP Immunol,1995,100(3):446-451.
[58]Dong Y,Xi H,Yu Y,et al.Effects of oxymatrine on the serum levels of T helper cell 1 and 2 cytokines and the expression of the S gene in hepatitis B virus S gene transgenic mice:a study on the anti-hepatitis B virus mechanism of oxymatrine [J] . J Gastroenterol Hepatol, 2002 ,17(2): 1299 -1306.
[59] Matima G, Roasol S, Cameei P, et al. Immunopathogenesis of hepatitis B virus recurrence after liver transplantation [J] .Transplantation, 2000, 69(12): 559 -568.
[1]R Mohamed,P Desmond,D Jin Suh,et al.Practical difficulties in the management of hepatitis B in the Asia-Pacific region[J].J Gastroenterol Hepatol,2004,19:958-969.
[2]Huang CF,Lin SS,Ho YC.The immune response induced by hepatitis B virus principal antigens[J].Cell Mol Immunol,2006,3(2):97-106.
[3]徐承富,厉有名.NKT细胞与肝脏疾病[J],中华肝脏病杂志,2007,15(5):399-400.
[4]邢汉前,辛绍杰,陈黎明.慢性乙型肝炎病毒感染的免疫机制[J].国际流行病学传染病杂志,2006,33(3)177-180.
[5]Huang Y,Chen Z,Jia H,et al.Induction of Tcl response and enhanced cytotoxic T lymphocyte activity in mice by dendritic cells transduced with adenovirus expressing HBsAg[J].Clin Immunol 2006;119:280-290.
[6]Fu-Sheng Wang,Li-He Xing,Ming-Xu Liu,et al.Dysfunction of peripheral blood dendritic cells from patients with chronic hepatitis B virus infection[J].World J Gastroenterol,2001,7(4):537-541.
[7]刘庆峰,张政,姚金霞等.CpG ODN2216刺激慢性乙型肝炎患者浆样树突状细胞表型和功能的变化[J].中华肝脏病杂志,2006,14(10):725-728.
[8]王凯,陈龙岩,王兵等.慢性乙型肝炎患者树突状细胞表型的研究[J].中华实验和临床病毒学杂志,2006,20(3):250-253.
[9]Zhang Z,Chen D,Yao J.Increased infiltration of intrahepatic DC subsetients with chronic hepatitis B[J].Clin Immunol,2007,122(2):173-180.
[10]陈明泉,施光峰,卢清等.不同病毒载量的慢性乙型肝炎患者外周血树突状细胞的表型和功能[J].中华肝脏病杂志,2007,15(1):19-23.
[11]Amir S and Yosef S.Inhibition of hepatitis B virus expression and replication by RNA interference[J].Hepatology,2003,37:764-770.
[12]何登明,毛青,王宇明等.慢性乙型肝炎患者拉米夫定治疗前后血清IL-2和IFN-γ水平变化[J].实用肝脏病杂志,2004,7(2):91-93.
[13]Falasca K,Ucciferri C,Dalessandro M,etal.Cytokine patterns correlate with liver damage in patients with chronic hepatitis B and[J]C.Ann Clin Lab Sci.2006Spring;36(2):144-150.
[14]Rigopoulou EI,Suri D,Chokshi S,et al.Lamivudine plus interleukin-12combination therapy in chronic hepatitis B:antiviral and immunological activity[J].Hepatology,2005,42(5):1028-1036.
[15]马清峰,王威,李丽等.慢性乙型肝炎患者血清和外周血单个核细胞IL-18水平与HBV感染的关系[J].肝脏,2007,12(2):112-114.
[16]Roncarolo MG,Levings MK.The role of different subsets of T regulatory cells in controlling autoimmunity[J].Curr Opin Immunol,2000,12:676-683.
[17]Hori S,Nomura T,Sakaguchi S.Control of regulatory T cell development by the transcripti-on factor Foxp3[J].Science,2003,299:1057-1061.
[18]Shevach EM,McHugh RS,Piccirillo CA,Thomton AM.Control of T-cell activation by CD4~+CD25~+ suppressor T cells[J].Immunol Rev,2001,182:58-67.
[19]Kondo Y,Kobayashi K,Ueno Y.Mechanism of Y cell hyporesponsiveness to HBcAg is associated with regulatory T cells in chronic hepatitis B[J].World J Gastroenterol,2006,21:12(27):4310-4317.
[20]Franzese O,Kennedy PT,Gehring AJ,et al.Modulation of the CD8+T cell response by CD4+CD25+ regulatory T cells in patients with hepatitis B virus infection[J].J Virol,2005,79:3322-3328.
[21]Xu D,Fu J,Jin L,Wang FS,et al.Circulating and Liver Resident CD4~+CD25~+Regulatory T Cells Actively Influence the Antiviral Immune Response and Disease Progression in Patients with Hepatitis B[J].J Immunol,2006,1;177(1):739-747.
[22]福军亮,徐东平,赵平等.急慢性乙型肝炎患者外周血调节性T细胞鉴定与临床意义分析[J].中华医学杂志,2006,86(22):1522-1525.
[23]Stoop JN,van der Molen RG,Kuipers EJ.Inhibition of viral replication reduces regulatory T cells and enhances the antiviral immune response in chronic hepatitis B[J].Virology,2007,361,1(25):141-148.
[24]福军亮,徐东平,施明等.乙型肝炎患者外周血CD4~+CD25~+调节性T细胞表型与功能分析[J].中华内科杂志,2006,45(8):642-645.
[25]Bauer T,Gunther M,Bienzle U.Vaccination against hepatitis B in liver transplant recipients:Pilot analysis of cellular immune response shows evidence of HBsAg-specific regulatory T cells[J].Liver Transpl,2007,13(3):434-442.